- Home
- FBRX vs MAIA Comparison
FBRX vs MAIA Comparison
Compare FBRX & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- MAIA
- Stock Information
- Founded
- FBRX N/A
- MAIA 2018
- Country
- FBRX United States
- MAIA United States
- Employees
- FBRX N/A
- MAIA N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- MAIA Health Care
- Exchange
- FBRX Nasdaq
- MAIA Nasdaq
- Market Cap
- FBRX 44.8M
- MAIA 46.7M
- IPO Year
- FBRX N/A
- MAIA 2022
- Fundamental
- Price
- FBRX $10.37
- MAIA $1.94
- Analyst Decision
- FBRX Strong Buy
- MAIA
- Analyst Count
- FBRX 3
- MAIA 0
- Target Price
- FBRX $80.50
- MAIA N/A
- AVG Volume (30 Days)
- FBRX 67.3K
- MAIA 200.5K
- Earning Date
- FBRX 05-15-2025
- MAIA 05-09-2025
- Dividend Yield
- FBRX N/A
- MAIA N/A
- EPS Growth
- FBRX N/A
- MAIA N/A
- EPS
- FBRX N/A
- MAIA N/A
- Revenue
- FBRX N/A
- MAIA N/A
- Revenue This Year
- FBRX N/A
- MAIA N/A
- Revenue Next Year
- FBRX N/A
- MAIA N/A
- P/E Ratio
- FBRX N/A
- MAIA N/A
- Revenue Growth
- FBRX N/A
- MAIA N/A
- 52 Week Low
- FBRX $4.11
- MAIA $1.40
- 52 Week High
- FBRX $28.68
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- FBRX 63.47
- MAIA 59.02
- Support Level
- FBRX $7.78
- MAIA $1.71
- Resistance Level
- FBRX $13.84
- MAIA $1.81
- Average True Range (ATR)
- FBRX 1.38
- MAIA 0.09
- MACD
- FBRX 0.20
- MAIA 0.01
- Stochastic Oscillator
- FBRX 50.44
- MAIA 98.28
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.